Search results
Added:
4 months ago
Source:
Radcliffe CVRM
Worsening kidney function is a known prognostic factor in heart failure with reduced ejection fraction (HFrEF), but a new analysis suggests this decline accelerates up to a year before a major heart failure (HF) event. The study examined data from two clinical trials, EPHESUS and EMPHASIS-HF, and the real-world BARCELONA cohort.¹This post-hoc analysis assessed longitudinal changes in estimated…
View more
ESC 24: MRAs in HF
Added:
1 year ago
Video
Hyperkalaemia in Acute Heart Failure: An Asian Population Study
Added:
9 months ago
Original Research
Added:
10 months ago
In this short interview, Dr Mohammed El-Sheikh discusses the key findings and clinical relevance of his recently published article, “Associations of Obesity and Prognostic Nutritional Index on 1-Year Mortality in Patients with Acute Heart Failure.”
View more
Added:
11 months ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure…
View more
Added:
5 months ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents findings from a randomized clinical trial comparing medically tailored meals versus produce supplements on heart failure readmissions and emergency department visits.The study was conducted across two centers in Dallas, Texas. Patients were randomized within two weeks following heart…
View more
Added:
1 year ago
ESC Congress 2024 — Finerenone improved outcomes in two trials in patients with CKD with T2D, and in patients with HFmrEF and HFpEF.Investigator, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) joins us in London to discuss the findings from the FINE-HEART pooled analysis (Bayer).FINE-HEART is a pre-specified, exploratory pooled analysis combining data from three phase III clinical…
View more
Added:
8 months ago
Source:
Radcliffe Cardiology
The US Food and Drug Administration (FDA) has approved the non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) finerenone (Kerendia, Bayer). The new indication is for adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40% to reduce the risk of cardiovascular death, hospitalisation for heart failure, and urgent heart failure visits.¹ The…
View more
Added:
9 months ago
In this short interview, we are joined by Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) to discuss the key updates and recommendations from the 2025 ACC Scientific Statement on the Management of Obesity in Adults with Heart Failure.Interview Questions:1. What is the current research landscape for heart failure patients with obesity?2. What are the new recommendations in this scientific…
View more
Eileen O’Meara
Research Area(s) / Expertise:
Job title: Professor of Medicine
Author